Alvotech (ALVO) Income from Discontinued Operations (2021 - 2026)
Alvotech (ALVO) posted Income from Discontinued Operations of 44000.0 for Q1 2026, down 94.73% on a QoQ basis from 835000.0 in Q3 2025, and down 99.73% year-over-year from 16259000.0 in Q1 2025.
Alvotech (ALVO) Income from Discontinued Operations (2021 - 2026) Analysis & Trends
Alvotech's Income from Discontinued Operations history runs 6 years deep, the most recent figure standing at 44000.0 for Q1 2026.
- Quarterly Income from Discontinued Operations fell 99.73% year-over-year to 44000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 39866000.0 (up 106.07% YoY) and the FY2022 annual result came in at 38067000.0, down 20.18% from the prior year.
- Income from Discontinued Operations was 44000.0 for Q1 2026 at Alvotech, down from 835000.0 in the prior quarter.
- Across five years, Income from Discontinued Operations topped out at 49854000.0 in Q3 2023 and bottomed at 5138438.0 in Q2 2024.
- A 5-year average of 12925733.33 and a median of 13357000.0 in 2024 frame the typical range for Income from Discontinued Operations.
- Annual changes were most pronounced in 2024 — Income from Discontinued Operations slumped 110.31% — and 2025, when it surged 252447.37%.
- Alvotech's Income from Discontinued Operations stood at 17073000.0 in 2022, then soared by 192.0% to 49854000.0 in 2023, then slumped by 110.29% to 5132000.0 in 2024, then surged by 116.27% to 835000.0 in 2025, then slumped by 94.73% to 44000.0 in 2026.
- Business Quant data shows ALVO's Income from Discontinued Operations at 44000.0 in Q1 2026, 835000.0 in Q3 2025, and 22728000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Alvotech | 907.91 Mn | 907.91 Mn | 5.09 Mn | 44,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 44,000.00 |
| Sep 30, 2025 | 835,000.00 |
| Jun 30, 2025 | 22.73 Mn |
| Mar 31, 2025 | 16.26 Mn |
| Dec 31, 2024 | -5.13 Mn |
| Sep 30, 2024 | 13.36 Mn |
| Jun 30, 2024 | -5.14 Mn |
| Mar 31, 2024 | 6,438.00 |
| Aug 31, 2023 | 49.85 Mn |
| Jun 30, 2023 | 49.82 Mn |
| Mar 31, 2023 | 29,380.00 |
| Dec 31, 2022 | 17.07 Mn |
| Aug 31, 2022 | 17.07 Mn |
| Jun 30, 2022 | -1.09 Mn |
| Mar 31, 2022 | 18.16 Mn |
| Dec 31, 2021 | -261,000.00 |
| Sep 30, 2021 | 22.04 Mn |